ClinicalTrials.gg
CompletedNCT00550173Updated Feb 13, 2013Results posted

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and erlotinib in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 29 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
40th of 223
247 · median 64
Started
2007
with 11 others
Phase 2
128 of 227
12 open now
Registered
64th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 40th largest by enrollment of the 223 interventional ones that give a count, is one of 12 that started in 2007, is one of 128 in phase 2, and was the 64th registered.

Carcinoma, Non-Small-Cell Lung

7,624 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in patients who have never smoked and have locally advanced or metastatic Nonsquamous Non-Small Cell Lung Cancer who have failed a first-line chemotherapy treatment.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with locally advanced or nonsquamous non-small cell lung cancer
  • Patients must be non-smokers
  • Patients must have at least one
  • Performance status of 0 to 2 on the Scale
  • Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication
  • Patients who have previously received treatment with drugs against the human epidermal growth factor receptors
  • Patients who have previously received treatment with drugs which have similar targets as Pemetrexed
  • Patients who have any known significant ophthalmologic abnormalities of the surface of the eye
  • Patients who have a history of severe reaction to erlotinib or pemetrexed
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Erlotinib

    Pemetrexed 500 milligrams per meter squared (mg/m\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.

    Drug: pemetrexed · Drug: erlotinib

  • Active comparator
    Erlotinib

    Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.

    Drug: erlotinib

  • Active comparator
    Pemetrexed

    Pemetrexed 500 mg/m\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.

    Drug: pemetrexed

Interventions

  • 500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops

    Also known as: LY231514, Alimta

  • 150 mg, orally, once daily until progression or unacceptable toxicity develops

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.

    Time frame: Randomization to measured PD up to 38 months

Secondary outcomes

  1. Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]

    TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.

    Time frame: Randomization to measured disease progression up to 38 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to the date of death from any cause.

    Time frame: Baseline to date of death from any cause up to 45.5 months

  3. Number of Participants With Adverse Events

    A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.

    Time frame: Randomization up to 39 months

  4. Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.

    Time frame: Randomization to disease progression up to 38 months

  5. Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)

    TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).

    Time frame: Randomization to first date of worsening of any of 6 LCSS symptom specific items or up to 12.4 months

  6. Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status

    EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.

    Time frame: Randomization to date of PD or death up to 38 months

  7. Probability of OS at 12 Months

    OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.

    Time frame: Month 12

07

Results

Posted Feb 13, 2013

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + ErlotinibErlotinibPemetrexed
Started818284
Qualified participants788280
Not discontinued at 18 months91911
Completed91911
Not completed726373
Withdrew: Death453850
Withdrew: Physician decision122
Withdrew: Withdrawal by subject91217
Withdrew: Sponsor decision1371
Withdrew: Lost to follow-up443

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS is defined as the time from randomization to the first date of progressive disease (PD; either objectively determined or clinical progression) or death from any cause. PD was defined as at least a 20% increase in sum of longest diameter of target lesions as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 guidelines. Time to disease progression was censored at the date of death.

Time frame:
Randomization to measured PD up to 38 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPemetrexed + ErlotinibErlotinibPemetrexed
Progression-Free Survival (PFS)7.4 (4.4 to 12.9)3.8 (2.7 to 6.3)4.4 (3.0 to 6.0)
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Cox · p = 0.003 (If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\<0.05.)Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Cox · p = 0.002 (If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\<0.05.) · Hazard ratio (hr): 0.57 · 95% CI 0.40 to 0.81Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Cox · p = 0.005 (If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\<0.05.) · Hazard ratio (hr): 0.58 · 95% CI 0.39 to 0.85Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Erlotinib vs Pemetrexed · Regression, Cox · p = 0.959 (If global test across 3 arms is significant at a 2-sided 0.2 level, then conduct 2-sided pairwise tests between combination and each single agent under the global model. Significance is claimed only if both the global and pairwise tests p\<0.05.) · Hazard ratio, log: 0.99 · 95% CI 0.70 to 1.40Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
SecondaryPercentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]

TRR was defined as the number of responders (complete or partial) divided by the number of participants qualified for tumor response, as assessed using the RECIST version 1.0 guideline, multiplied by 100. RECIST guidelines: CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; PR was defined as at least a 30% decrease in sum of longest diameter of target lesions.

Time frame:
Randomization to measured disease progression up to 38 months
Reported as:
Number · percentage of participants
Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
percentage of participantsPemetrexed + ErlotinibErlotinibPemetrexed
Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]44.729.310.0
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Logistic · p = <0.001Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Logistic · p = 0.031 · Odds ratio (or): 2.09 · 95% CI 1.07 to 4.09Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Logistic · p = <0.001 · Odds ratio (or): 7.68 · 95% CI 3.19 to 18.48Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Erlotinib vs Pemetrexed · Regression, Logistic · p = 0.004 · Odds ratio, log: 0.27 · 95% CI 0.11 to 0.66Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to the date of death from any cause.

Time frame:
Baseline to date of death from any cause up to 45.5 months
Reported as:
Median · months
Overall Survival (OS)
monthsPemetrexed + ErlotinibErlotinibPemetrexed
Overall Survival (OS)20.5 (17.1 to 25.0)22.8 (18.2 to 29.5)17.7 (11.8 to 25.3)
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Cox · p = 0.194Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Cox · p = 0.747 · Hazard ratio (hr): 1.08 · 95% CI 0.69 to 1.67Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Cox · p = 0.168 · Hazard ratio (hr): 0.75 · 95% CI 0.49 to 1.13Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Erlotinib vs Pemetrexed · Regression, Cox · p = 0.094 · Hazard ratio (hr): 1.44 · 95% CI 0.94 to 2.21Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
SecondaryNumber of Participants With Adverse Events

A summary of serious and all other non-serious adverse events (AEs), which include AEs reported for pharmacological toxicity, is located in the Reported Adverse Event module.

Time frame:
Randomization up to 39 months
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsPemetrexed + ErlotinibErlotinibPemetrexed
Serious Adverse Events251822
Other Non-Serious Adverse Events727667
SecondaryPercentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)

DCR was defined as the percentage of participants with CR, PR, or SD divided by the number of randomized and treated participants as assessed using the RECIST criteria. CR was defined as the disappearance of all target lesions; PR was defined as 1) at least a 30% decrease in sum of longest diameter of target lesions or 2) complete disappearance of target lesions, with persistence (but not worsening) of 1 or more non-target lesions; PD was defined as at least a 20% increase in sum of longest diameter of target lesions; SD was defined as small changes that did not meet the above criteria.

Time frame:
Randomization to disease progression up to 38 months
Reported as:
Number · percentage of participants
Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)
percentage of participantsPemetrexed + ErlotinibErlotinibPemetrexed
Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)64.552.456.3
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Logistic · p = 0.306Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Logistic · p = 0.127 · Odds ratio (or): 1.66 · 95% CI 0.87 to 3.18Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Logistic · p = 0.318 · Odds ratio (or): 1.40 · 95% CI 0.72 to 2.71Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Erlotinib vs Pemetrexed · Regression, Logistic · p = 0.599 · Odds ratio (or): 1.18 · 95% CI 0.63 to 2.22Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
SecondaryTime to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)

TWS assessed using the LCSS a participant rated lung cancer instrument which consisted of 9 disease related symptoms and quality of life (QoL) items, with 6 subscales related to major lung cancer symptoms (appetite, cough, fatigue, dyspnea, hemoptysis, and pain) and 3 summation items related to QoL (activity status, symptomatic distress, and overall QoL). Each item is marked on a visual analog scale (VAS) 0 (low symptoms/QoL items) to 100 (high symptoms/QoL items). The mean of the 6 subscales is used to calculate the average symptom burden index. TWS was measured from the date of study enrollment to the first date of a worsening in any 1 of the 6 LCSS symptom-specific items (as defined by a VAS 15-mm increase from baseline in the patient-reported score for any of these 6 items).

Time frame:
Randomization to first date of worsening of any of 6 LCSS symptom specific items or up to 12.4 months
Reported as:
Median · months
Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)
monthsPemetrexed + ErlotinibErlotinibPemetrexed
Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)1.0 (0.9 to 1.6)0.8 (0.8 to 1.2)1.5 (1.0 to 2.1)
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Cox · p = 0.013Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Cox · p = 0.007 (Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.) · Hazard ratio (hr): 0.59 · 95% CI 0.41 to 0.87Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Cox · p = 0.700 · Hazard ratio (hr): 0.92 · 95% CI 0.62 to 1.38Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
  • Erlotinib vs Pemetrexed · Regression, Cox · p = 0.023 · Hazard ratio (hr): 0.64 · 95% CI 0.44 to 0.94Model is adjusted to covariates ECOG PS (0/1 vs.2), histological subtype (adeno vs. non-adeno), race (East Asian and non-East Asian) and gender.
SecondaryNumber of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status

EGFR mutation status was defined as: participants with any mutations detected were categorized as mutated and participants without any mutations detected were categorized as non-mutated.

Time frame:
Randomization to date of PD or death up to 38 months
Reported as:
Number · participants
Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status
participantsPemetrexed + ErlotinibErlotinibPemetrexed
Mutated7 (7.1 to —)89
Non-mutated1063
Mutation status unknown (treated as missing)523
Statistical analysis
  • Pemetrexed + Erlotinib vs Erlotinib vs Pemetrexed · Regression, Cox · p = 0.040
  • Pemetrexed + Erlotinib vs Erlotinib · Regression, Cox · p = 0.241 · Hazard ratio (hr): 0.62 · 95% CI 0.27 to 1.38
  • Pemetrexed + Erlotinib vs Pemetrexed · Regression, Cox · p = 0.011 · Hazard ratio (hr): 0.32 · 95% CI 0.14 to 0.78
  • Erlotinib vs Pemetrexed · Regression, Cox · p = 0.128 · Hazard ratio (hr): 1.90 · 95% CI 0.83 to 4.36
SecondaryProbability of OS at 12 Months

OS time is censored at the date of last contact for participants who were still alive or lost to follow-up.

Time frame:
Month 12
Reported as:
Number · percent chance of survival
Probability of OS at 12 Months
percent chance of survivalPemetrexed + ErlotinibErlotinibPemetrexed
Probability of OS at 12 Months40.2 (28.3 to 51.8)26.2 (17.2 to 36.1)18.1 (9.1 to 29.4)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Erlotinib—25/78 (32.1%)72/78 (92.3%)
Erlotinib—18/83 (21.7%)76/83 (91.6%)
Pemetrexed—22/80 (27.5%)67/80 (83.8%)
Most frequent serious events
Showing 10 of 80
Most frequent serious events
EventPemetrexed + ErlotinibErlotinibPemetrexed
DyspnoeaRespiratory, thoracic and mediastinal disorders2/786/831/80
DiarrhoeaGastrointestinal disorders4/780/832/80
HyponatraemiaMetabolism and nutrition disorders2/780/834/80
PyrexiaGeneral disorders3/782/831/80
NeutropeniaBlood and lymphatic system disorders0/780/833/80
Back painMusculoskeletal and connective tissue disorders0/782/833/80
Respiratory tract infectionInfections and infestations0/783/830/80
AstheniaGeneral disorders2/782/831/80
PneumoniaInfections and infestations2/781/831/80
SepsisInfections and infestations2/780/831/80
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPemetrexed + ErlotinibErlotinibPemetrexed
RashSkin and subcutaneous tissue disorders41/7843/838/80
DiarrhoeaGastrointestinal disorders29/7829/838/80
CoughRespiratory, thoracic and mediastinal disorders15/7828/8313/80
VomitingGastrointestinal disorders25/7810/8312/80
Dry skinSkin and subcutaneous tissue disorders12/7825/832/80
Decreased appetiteMetabolism and nutrition disorders23/7815/8319/80
NauseaGastrointestinal disorders21/7810/8317/80
FatigueGeneral disorders20/789/8317/80
PruritusSkin and subcutaneous tissue disorders17/7820/834/80
Neutrophil count decreasedInvestigations16/781/837/80

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Mean56.0 ± 11.7253.9 ± 10.4956.1 ± 13.0455.3 ± 11.78
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Female585445157
Male20283583
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Caucasian1861135
African2013
East Asian (enrolled in an East Asian country)414943133
East Asian (enrolled in non-East Asian Country)4217
West Asian13252462
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Australia3003
Brazil155828
China14171546
Hong Kong0325
India15272567
Korea, Republic of20201353
Taiwan791329
United Kingdom4149
Height at Baseline
Height at Baseline(centimeter (cm))Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Mean159.3 ± 8.70160.3 ± 8.38160.1 ± 8.84159.9 ± 8.61
Weight at Baseline
Weight at Baseline(kilogram (kg))Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Mean59.6 ± 11.7659.9 ± 12.1758.9 ± 10.8259.5 ± 11.56
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per meter squared (kg/m^2))Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Mean23.5 ± 4.5423.3 ± 3.8723.0 ± 3.8723.2 ± 4.09
Body Surface Area (BSA)
Body Surface Area (BSA)(meter squared (m^2))Pemetrexed + ErlotinibErlotinibPemetrexedTotal
Mean1.6 ± 0.171.6 ± 0.181.6 ± 0.171.6 ± 0.17

2 further baseline measures are reported on the registry.

08

Study locations

29 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barretos, 14784700, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ijui, 98700 000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 01277-900, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100730, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanning, 530000, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sha Tin, Hong Kong
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 380016, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bhopal, 462001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyderabaad, 500082, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jaipur, 302013, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochin, 682304, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kolkata, 700 026, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madurai, 625020, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mohali, 160062, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mumbai, 400 026, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Delhi, 110017, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vishakhapatnam, 530002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jin-Ju-Si, 660-702, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 138-736, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suwon-City, 442-723, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changhua, 500, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 407, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tao-Yuan, 333, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poole, Dorset BH15 2JB, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chelmsford, Essex CM1 7ET, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aberdeen, Scotland AB25 2ZN, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guildford, Surrey GU2 7XX, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, Wang J, Kim HK, Sahoo TP, Digumarti R, Wang X, Altug S, Orlando M. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer. 2013 Oct;49(15):3111-21. doi: 10.1016/j.ejca.2013.06.035. Epub 2013 Jul 24. PubMed 23890768 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2007
First posted
Oct 29, 2007
Start
Nov 2007
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Feb 13, 2013
Last update
Feb 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00550173
Responsible party
Sponsor
First posted
Oct 29, 2007
Start date
Nov 2007
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Feb 13, 2013
Last update
Feb 13, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Erlotinib

Start the discussion